From: Prognostic significance of galectin-1 expression in patients with cancer: a meta-analysis
Study | Country | Cancer | Case number | Median age (year, range) | M/F | Stage | Gal-1 (±) NO. | Cut-off | Multivariate analysis | HR and 95% CI |
---|---|---|---|---|---|---|---|---|---|---|
Wu [5] | Japan | CCA | 78 | NA | 50/28 | TNM I–IV | (45/33) | IRS ≥ 3 | No | SC |
Chen [6] | China | gastric | 214 | Mean 64.5 | 129/85 | TNM I–IV | (138/76) | IRS ≥ 2 | No | SC |
Noda [9] | Japan | GSCC | 80 | Mean 63.8 | 39/41 | TNM I–IV | (22/58) | IHC > 50% | No | SC |
Chong [8] | China | Gastric | 111 | NA | NA | TNM I–IV | (61/50) | IHC > 20% | No | SC |
Zhang [10] | China | HCC | 209 | NA | 179/30 | TNM I–IV | (128/81) | IHC > 20% | No | SC |
Huang [13] | Tainan | RCC | 45 | NA | 31/14 | TNM I–IV | (25/20) | H-score > median | No | SC |
Le [14] | USA | HNSCC | 101 | Median 58 | 84/17 | TNM I–IV | (56/44) | IRS ≥ 3 | No | SC |
Schulz [15] | Germany | Ovarian | 150 | Median 62 (31–88) | 0/150 | FIGO I–IV | (102/48) | IRS > 1 | No | SC |
Chen [7] | China | Gastric | 108 | NA | 61/47 | TNM I–IV | (68/40) | IRS ≥ 2 | Yes | Report |
You [11] | China | HCC | 162 | NA | 127/35 | TNM I–IV | (105/57) | IRS ≥ 2 | Yes | Report |
Wu [12] | China | HCC | 386 | NA | 341/45 | TNM I–IV | (189/197) | NA | Yes | Report |
Kamper [19] | Denmark | cHL | 143 | 35 | 78/80 | Ann Arbor I–IV | (35/108) | NA | No | Report |
Ye [20] | China | LSCC | 187 | Mean 52.4 | 179/8 | TNM I–IV | (102/85) | NA | No | SC |
Szoke [17] | Hungary | NSCLC | 94 | Mean 58.8 | 84/10 | TNM I–III | (40/54) | NA | No | SC |
Carlini [18] | Argentina | NSCLC | 103 | Median 64 (45–85) | 69/34 | TNM I–III | (53/47) | IRS > 1 | No | SC |
Van Woensel [21] | Belgium | GBM | 349 | NA | NA | NA | (174/175) | Median gene expression | No | Report |
Chou [22] | China | GBM | 45 | NA | 27/18 | NA | (34/11) | IHC > 35% | No | Report |
Chen [16] | China | EOC | 109 | NA | 0/109 | FIGO | (91/18) | IRS ≥ 3 | Yes | Report |